Assessment of Fatigue in Rheumatoid Arthritis (by Functional Assessment of Chronic Illness Therapy–Fatigue Score) and Its Relation to Disease Activity and Anemia

Singh, Harpreet; Arya, Sidharth; Talapatra, Paulomi; Lather, Kunal; Mathur, Rekha; Singhania, Amit; Chaudhary, Vikas

doi:10.1097/rhu.0000000000000073

Cited by 32 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also necessary to remember that fatigue can be associated with side effects of traditional disease modifying drugs, such as methotrexate and leflunomide [32]. Among women with psoriatic arthritis in our study, the fatigue significantly increased during methotrexate therapy (p = 0.037), we did not observe such a correlation among women with psoriasis, which could be caused by lower methotrexate doses applied in the treatment of skin disease (p = 0.045).…”

Section: Discussioncontrasting

confidence: 59%

Prevalence and severity of fatigue in psoriasis and psoriatic arthritis

Krajewska–Włodarczyk

Owczarczyk‐Saczonek

Placek

2020

pdia

View full text Add to dashboard Cite

Introduction: Fatigue is an important and underrated symptom of many chronic diseases. Aim: The evaluation of incidence and severity of fatigue as well as the influence of selected factors on fatigue in patients with psoriasis and psoriatic arthritis (PsA). Material and methods: The study included 60 patients with PsA, 58 patients with psoriasis and 61 persons in the control group aged 35-70 years. Assessment of fatigue was conducted using a fatigue subscale from the FACIT-F questionnaire. Severity of skin lesions and arthritis was determined with PASI and DAS28, respectively, as well as the number of painful and swollen joints, severity of pain and inflammatory markers. Results: Severe fatigue occurred in 17%, 28%, and 1.6% of patients with psoriasis, PsA and the control group, respectively. Severity of fatigue was significantly higher in patients with PsA as compared to patients with psoriasis (p < 0.0001). In patients with psoriasis and PsA, it decreased along with the duration of psoriasis (r = 0.291, p < 0.05 vs. r = 0.382, p < 0.05, respectively). No significant correlation was found between the duration of PsA and fatigue. After using the linear regression model, severity of fatigue in psoriasis was correlated with the age of patients and the duration of psoriasis, while in PsA, with the duration of psoriasis, PASI, DAS28, CRP and the number of painful joints. Conclusions: The results of this study may indicate the need for routine fatigue examination among people with psoriasis and psoriatic arthritis.

show abstract

Section: Discussioncontrasting

confidence: 59%

Prevalence and severity of fatigue in psoriasis and psoriatic arthritis

Krajewska–Włodarczyk

Owczarczyk‐Saczonek

Placek

2020

pdia

View full text Add to dashboard Cite

show abstract

“…Fatigue experienced by patients with RA can be strongly related to disease activity as assessed using DAS28 [24], and improvements in fatigue with treatment have been shown to correlate with reductions in disease activity [22]. Examination of the relationship between fatigue and disease activity in biologic-naïve patients with RA initiating TNF-inhibitor therapy found that approximately half of the effect on fatigue associated with reduction in clinical symptoms (measured by DAS28 [CRP]) was indirect, mediated through a reduction in pain [25].…”

Section: Discussionmentioning

confidence: 99%

Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept

et al. 2017

View full text Add to dashboard Cite

IntroductionA post hoc analysis of three randomized controlled trials of abatacept in rheumatoid arthritis (RA) was conducted to explore the effect of abatacept on fatigue in RA and its correlation with other outcomes.MethodsIn this analysis of AGREE (early RA) and AIM and ATTAIN (established RA), changes in baseline fatigue (0–100 mm scale), pain, sleep (AIM and ATTAIN only) and Disease Activity Score (DAS) 28 (C-reactive protein; CRP) were calculated at days 29, 85, and 169. Agreement between improvements ≥minimum clinically important differences (MCID) in fatigue and other outcomes were evaluated using agreement statistics (kappa) in each study and at each time point.ResultsOf 1536 patients (mean disease duration: 6.2 months [AGREE], 8.5 years [AIM], 12.2 years [ATTAIN]), mean (SE) decreases in fatigue from baseline to day 169 with abatacept were 28.9 (1.7), 25.3 (1.2), and 21.9 (1.6) in AGREE, AIM, and ATTAIN, respectively, with corresponding decreases of 16.0, 13.7, and 13.4 at day 29. Most patients (67.8%; 624/920) reported improvements ≥MCID in fatigue with abatacept at day 169; 79.2% (671/847) and 57.8% (388/671) reported improvements ≥MCID in pain and sleep, respectively; 18.9% (158/836) were in DAS28 (CRP) remission. Agreement between improvement in fatigue and other outcomes was low (kappa range 0.30–0.51 [pain], 0.14–0.26 [sleep], and 0.02–0.12 [DAS28 (CRP) remission]).ConclusionsAbatacept resulted in rapid improvements in fatigue and pain in patients with RA. However, low agreement between improvements in these outcomes indicates that fatigue and other outcomes including pain and sleep may represent different domains of response.FundingBristol-Myers Squibb.Electronic supplementary materialThe online version of this article (doi:10.1007/s40744-017-0054-6) contains supplementary material, which is available to authorized users.

show abstract

“…However, when assessing the content of these items, the health-related problems might also be relevant for employees with other chronic diseases. For instance, fatigue is indicated as one of the most unpleasant problems among patients with rheumatoid arthritis [27], and uncertainty about the future is also experienced by patients with multiple sclerosis (MS) [28]. Workers with a chronic health condition (e.g., musculoskeletal conditions) also experienced employment difficulties, such as reduced work ability [29].…”

Section: Discussionmentioning

confidence: 99%

Quality of Working Life of cancer survivors: associations with health- and work-related variables

Jong

Tamminga

Frings‐Dresen

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

PurposeThis study aimed to (1) describe the Quality of Working Life (QWL) of cancer survivors and (2) explore associations between the QWL of cancer survivors and health- and work-related variables.MethodsEmployed and self-employed cancer survivors were recruited through hospitals and patient organizations. They completed the Quality of Working Life Questionnaire for Cancer Survivors (QWLQ-CS) and health- and work-related variables in this cross-sectional study. The QWL scores of cancer survivors were described, and associations between QWL and health- and work-related variables were assessed.ResultsThe QWLQ-CS was completed by 302 cancer survivors (28% male) with a mean age of 52 ± 8 years. They were diagnosed between 0 and 10 years ago with various types of cancer, such as breast cancers, gastrointestinal cancers, urological cancers, and haematological cancers. The QWL mean score of cancer survivors was 75 ± 12 (0–100). Cancer survivors had statistically significant lower QWL scores when they had been treated with chemotherapy or when they reported co-morbidity (p ≤ 0.05). Cancer survivors without managerial positions, with low incomes or physically demanding work, and who worked a proportion of their contract hours had statistically significantly lower QWL scores (p ≤ 0.05).ConclusionsThis study described the QWL of cancer survivors and associations between QWL and health- and work-related variables. Based on these variables, it is possible to indicate groups of cancer survivors who need more attention and support regarding QWL and work continuation.

show abstract

Assessment of Fatigue in Rheumatoid Arthritis (by Functional Assessment of Chronic Illness Therapy–Fatigue Score) and Its Relation to Disease Activity and Anemia

Abstract: The fatigue experienced by the patients with RA is strongly associated with the severity of disease activity and is independent of anemia.

Cited by 32 publications

References 9 publications

Prevalence and severity of fatigue in psoriasis and psoriatic arthritis

Prevalence and severity of fatigue in psoriasis and psoriatic arthritis

Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept

Quality of Working Life of cancer survivors: associations with health- and work-related variables

Contact Info

Product

Resources

About